ArticleFrontiers in oncology2026

Cost-effectiveness of ramucirumab plus paclitaxel as maintenance therapy for patients with advanced HER2-negative gastric or gastroesophageal junction cancer.

Dong Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.